Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $6.57.

A number of research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Wall Street Zen raised Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 7th. Finally, Weiss Ratings upgraded Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 25th.

Insiders Place Their Bets

In other news, insider Daljit Singh Aurora sold 91,690 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1.50, for a total value of $137,535.00. Following the completion of the transaction, the insider directly owned 48,750 shares of the company’s stock, valued at $73,125. The trade was a 65.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 453,833 shares of company stock worth $701,219 over the last ninety days. Company insiders own 26.94% of the company’s stock.

Institutional Trading of Neumora Therapeutics

Large investors have recently made changes to their positions in the stock. Ieq Capital LLC purchased a new stake in Neumora Therapeutics during the 3rd quarter worth about $25,000. HBK Sorce Advisory LLC purchased a new position in Neumora Therapeutics in the 2nd quarter valued at about $26,000. The Manufacturers Life Insurance Company purchased a new position in Neumora Therapeutics in the 2nd quarter valued at about $44,000. AMG National Trust Bank acquired a new stake in shares of Neumora Therapeutics during the 2nd quarter worth about $74,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Neumora Therapeutics during the 2nd quarter worth about $130,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Price Performance

NASDAQ:NMRA traded down $0.00 during mid-day trading on Friday, hitting $0.43. 554,776 shares of the company’s stock traded hands, compared to its average volume of 1,722,527. The company has a debt-to-equity ratio of 1.19, a quick ratio of 4.50 and a current ratio of 4.50. The firm’s 50 day simple moving average is $0.60 and its 200 day simple moving average is $1.70. Neumora Therapeutics has a 1 year low of $0.32 and a 1 year high of $3.65. The company has a market cap of $80.59 million, a PE ratio of -0.35 and a beta of 3.12.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. Sell-side analysts expect that Neumora Therapeutics will post -0.84 EPS for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. Founded in 2020 and headquartered in Watertown, Massachusetts, the company researches potential medicines for conditions including depression, schizophrenia and agitation associated with Alzheimer’s disease. The company combines neuroscience research with data science and other computational approaches to identify disease targets and develop drug candidates. Its pipeline includes investigational medicines designed to act on specific biological pathways involved in brain disorders; these products are under development and are not approved treatments.